Description:
An ovarian cancer resource dedicated to the support and empowerment of ovarian cancer survivors and their families through the principle that medical and educational "information is power" in the fight against ovarian cancer -- thereby allowing all survivors to choose H*O*P*E*.
Contents:
PI3K Pathway: A Potential Ovarian Cancer Therapeutic Target?
…[T]here are several PI3K signaling pathway targeting drugs in clinical development for use against ovarian cancer and solid tumors, including GDC-0941, BEZ235, SF1126, XL-147, XL-765, BGT226, and PX-866. The results of two recent medical studies suggest that the use of PI3K-targeted therapies may offer an effective therapeutic approach for patients with advanced-stage and recurrent ovarian [...] 
“Decisions Are Made By Those Who Show Up”*
Responding to a threat of a funding reduction to the Department of Defense’s Ovarian Cancer Research Program, during the last week of October the Ovarian Cancer National Alliance urged advocates to contact their Members of Congress to appeal to the Appropriations Defense Subcommittee to increase funding for the research program. As a result of the [...] 
Nationwide Registry to “Match” Study Volunteers With Researchers
Individuals who want to participate in research studies can connect online with researchers nationwide through the first disease-neutral, volunteer recruitment registry. ResearchMatch.org is a not-for-profit secure Web site, designed to provide people who are interested in participating in research the opportunity to be matched with studies that may be the right fit for them.
NIH Announces [...] 
UCLA Researchers Significantly Inhibit Growth of Ovarian Cancer Cell Lines With FDA-Approved Leukemia Drug Dasatinib (Sprycel®)
The drug dasatinib (Sprycel®), approved for use by the U.S. Food and Drug Administration in patients with specific types of leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death, say UCLA researchers in the November 10th issue of the British Journal of Cancer. The drug, when paired with [...] 
Æterna Zentaris’ LHRH-Receptor Targeted Therapy AEZS-108 Produces Positive Preliminary Results in Advanced Stage Ovarian Cancer
Preliminary Phase II clinical study evaluation shows that primary efficacy endpoint has been met for patients with advanced-stage, platinum-resistant, taxane-pretreated ovarian cancer who were treated with the targeted therapy AEZS-108.
Æterna Zentaris Inc. , a global biopharmaceutical company focused on endocrine therapy and oncology, today announced positive efficacy data from a Phase II study with its [...] 
Unusual Metals May Forge New Ovarian & Colon Cancer Drugs
Drugs made using unusual metals could form an effective treatment against colon and ovarian cancer, including cancerous cells that have developed immunity to other drugs, according to research at the University of Warwick and the University of Leeds.
Drugs made using unusual metals could form an effective treatment against colon and ovarian cancer, including cancerous cells [...] 
U.S. Ovarian Cancer Research Funding Slashed In Half — Take Action & Call Your U.S. Congressman & Senators Today!
As a result of a recent U.S. Senate mark-up, the funding for the Department of Defense Ovarian Cancer Research Program (DOD OCRP) has been slashed in half from $20 million to $10 million. Research conducted under the DOD OCRP program is critical because it is solely dedicated to ovarian cancer. … Please help us [...] 
Endocyte’s EC145 Produces Significant Anti-Tumor Activity In Advanced Stage Chemoresistant Ovarian Cancer Patients
Endocyte, Inc., … presented data from a Phase 2a clinical trial for EC145, … In 49 women with advanced-stage ovarian cancer, EC145 was shown to have anti-tumor activity in a significant percentage of participants in the trial. …[T]he overall disease control rate, defined as stable disease, partial or complete response to therapy, was 40.8 [...] 
Modified Chemo Regime Increases Survival In Advanced Ovarian Cancer Patients But Adds Toxicity
Women with advanced ovarian cancer lived longer and without their tumors growing after receiving a modified regimen of a standard chemotherapy drug combination, Japanese researchers reported last week. In a large phase III clinical trial, women who received carboplatin every 3 weeks and a reduced dose of paclitaxel (Taxol®) once a week for 3 weeks [...] 
FDA Clears Vermillion’s “OVA1? Test To Determine Likelihood of Ovarian Cancer In Women With Pelvic Mass
The U.S. Food and Drug Administration cleared a test that can help detect ovarian cancer in a pelvic mass that is already known to require surgery. The test, called OVA1, helps patients and health care professionals decide what type of surgery should be done and by whom.
First Lab Test That Can Indicate Ovarian Cancer Prior [...] 
Barack Obama Proclaims September 2009 As National Ovarian Cancer Awareness Month
Yesterday, U.S. President Barack Obama designated September 2009 as National Ovarian Cancer Awareness Month. National Ovarian Cancer Awareness Month helps educate women and men about the importance of knowing the early warning signs and symptoms of the disease, scheduling routine doctor visits, and continuing robust scientific research.
Yesterday, U.S. President Barack Obama designated September [...] 
To Fight Cancer, Know The Enemy
An Op-Ed entitled “To Fight Cancer, Know the Enemy” was published in The New York Times on August 6, 2009. The author of the Op-Ed was James D. Watson, Ph.D. James Watson co-discovered the DNA double helix structure; a discovery for which he received the 1962 Nobel Prize for Physiology or Medicine. In the [...] 
UA Research Team Designing Holographic Imaging System For Ovarian Cancer
University of Arizona researchers Jennifer Barton and Ray Kostuk have received a five-year, $2.4 million grant from the National Institutes of Health to build the instrument that they hope will one day be used to monitor women at high risk for ovarian cancer.
Two University of Arizona [UA] researchers have formed a research team to [...] 
NCCN Updates Infection Guidelines To Include Information About H1N1 Virus (Swine Flu)
NCCN [National Comprehensive Cancer Network] recently updated the NCCN Clinical Practice Guidelines in Oncology™ for the Prevention and Treatment of Cancer-Related Infections to include information about the H1N1 virus, also known as “swine flu”. The NCCN Guidelines provide specific recommendations on the prevention, diagnosis, and treatment of the major common and opportunistic infections that afflict [...] 
FDA Issues Final Rules to Help Patients Gain Access to Investigational Drugs
The U.S. Food and Drug Administration (FDA) published two rules [on August 12, 2009] …that seek to clarify the methods available to seriously ill patients interested in gaining access to investigational drugs and biologics when they are not eligible to participate in a clinical trial and don’t have other satisfactory treatment options.
The U.S. Food and [...] 
Home
|
